Patients with moderate acne vulgaris Botulinum toxin type A, acne vulgaris, enlarged pore, oiliness
Conditions
Interventions
Normal saline injection 0.3 ml at forehead,Botulinum toxin type A 6 unit (dilution 1:5) injection 0.3 ml at forehead,Botulinum toxin type A 12 unit (dilution 1:2.5) injection 0.3 ml at forehead
Botulinum toxin type A 0 unit,Botulinum toxin type A 6 unit,Botulinum toxin type A 12 unit
Sponsors
Srinakharinwirot University
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Healthy patients age 18 to 45 years old, 2. Patients with moderate acne vulgaris according to Clinical practice guideline of acne of Dermatological society of Thailand, 3. Consent to study
Exclusion criteria
Exclusion criteria: 1. Received a forehead injection of botulinum toxin within 6 months before the study, 2. Received a forehead injection of hyaluronic acid (HA), biostimulator, or mesotherapy within 6 months before the study, 3. Received the systemic treatments before the study (3.1 Anti-inflammatory drugs or drugs that have an effect on the treatment of acnes such as oral corticosteroids, oral antibiotics, oral contraceptive pills or oral zinc supplement within 1 month before the study, 3.2 Drugs in retinoid group such as oral isotretinoin within 3 months before the study), 4. Received the topical drugs for acne such as topical antibiotics, topical retinoids, or topical corticosteroids within 1 month before the study, 5. History of botulinum toxin A allergy or allergy to any ingredients in botulinum toxin type A, 6. History of botulinum toxin A resistance, 7. History of neuromuscular disorders such as myasthenia gravis, Lambert-Eaton syndrome, 8. Current or active facial bacterial, fungal, or viral infection, 9. Pregnancy or lactation, 10. Cannot follow up throughout the study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acne vulgaris at baseline and at 2, 4, 8, 12, and 16 weeks after the intervention modified Total acne lesion count | — |
Secondary
| Measure | Time frame |
|---|---|
| Acne vulgaris at baseline and at 2, 4, 8, 12, and 16 weeks after the intervention Modified Global acne severity scale,Acne vulgaris at baseline and at 2, 4, 8, 12, and 16 weeks after the intervention modified Michaelson acne score,Pores size at baseline and at 2, 4, 8, 12, and 16 weeks after the intervention Pore size volume by Antera 3D,Sebum level at baseline and at 2, 4, 8, 12, and 16 weeks after the intervention Sebum level and percentage of sebum reduction by Sebumeter,Patient satisfaction score at 4 and 16 weeks after the intervention Visual analogue scale,Adverse effects at 2, 4, 8, 12, and 16 weeks after the intervention Skin infection, erythema, edema, bruising, facial asymmetry, and brow ptosis | — |
Countries
Thailand
Contacts
Public ContactVatanya Rungtiravatananon
Srinakharinwirot university
Outcome results
None listed